Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anders Pedersen

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
SLAS Discovery : Advancing Life Sciences R & D|March 29, 2023
Evaluating the affinity and kinetics of small molecule glycomimetics for human and mouse galectin-3 using surface plasmon resonanceHenry Kim, Nathalie Weidner, Céline Ronin, et al.
Pain|September 3, 2024
The physical activity paradox; exploring the relationship with pain outcomes. The Tromsø Study 2015-2016Mats Kirkeby Fjeld, Anders Pedersen Årnes, Bo Engdahl, et al.
European Journal of Pharmacology|November 11, 2024
Effect of GB1107, a novel galectin-3 inhibitor on pro-fibrotic signalling in the liverAlison C MacKinnon, Duncan C Humphries, Kimberley Herman, et al.
Frontiers in Endocrinology|February 28, 2022
Medications Activating Tubular Fatty Acid Oxidation Enhance the Protective Effects of Roux-en-Y Gastric Bypass Surgery in a Rat Model of Early Diabetic Kidney DiseaseWilliam P Martin, Yeong H D Chuah, Mahmoud Abdelaal, et al.
Cancer Chemotherapy and Pharmacology|March 14, 2023
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participantsVassilios Aslanis, Robert J Slack, Alison C MacKinnon, et al.
Journal of Medicinal Chemistry|December 12, 2024
Development and Characterization of a High-Affinity Selective Galectin-3 Mouse Tool Compound in Mouse Models of CancerKristoffer Peterson, Ulf J Nilsson, Lise Gravelle, et al.
Journal of Medicinal Chemistry|April 29, 2026
An Orally Available Halothiazole Glycomimetic as a Cancer-Targeting Dual Galectin-1 and Galectin-3 InhibitorFredrik R Zetterberg, Kristoffer Peterson, Ulf J Nilsson, et al.
Journal of Medicinal Chemistry|September 26, 2022
Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic DiseaseFredrik R Zetterberg, Alison MacKinnon, Thomas Brimert, et al.
Frontiers in Pharmacology|August 25, 2022
Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activationDuncan C Humphries, Ross Mills, Cecilia Boz, et al.
Journal of Medicinal Chemistry|May 28, 2024
Discovery of the Selective and Orally Available Galectin-1 Inhibitor GB1908 as a Potential Treatment for Lung CancerFredrik R Zetterberg, Kristoffer Peterson, Ulf J Nilsson, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
SLAS Discovery : Advancing Life Sciences R & D|March 29, 2023
Evaluating the affinity and kinetics of small molecule glycomimetics for human and mouse galectin-3 using surface plasmon resonanceHenry Kim, Nathalie Weidner, Céline Ronin, et al.
Pain|September 3, 2024
The physical activity paradox; exploring the relationship with pain outcomes. The Tromsø Study 2015-2016Mats Kirkeby Fjeld, Anders Pedersen Årnes, Bo Engdahl, et al.
European Journal of Pharmacology|November 11, 2024
Effect of GB1107, a novel galectin-3 inhibitor on pro-fibrotic signalling in the liverAlison C MacKinnon, Duncan C Humphries, Kimberley Herman, et al.
Frontiers in Endocrinology|February 28, 2022
Medications Activating Tubular Fatty Acid Oxidation Enhance the Protective Effects of Roux-en-Y Gastric Bypass Surgery in a Rat Model of Early Diabetic Kidney DiseaseWilliam P Martin, Yeong H D Chuah, Mahmoud Abdelaal, et al.
Cancer Chemotherapy and Pharmacology|March 14, 2023
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participantsVassilios Aslanis, Robert J Slack, Alison C MacKinnon, et al.
Journal of Medicinal Chemistry|December 12, 2024
Development and Characterization of a High-Affinity Selective Galectin-3 Mouse Tool Compound in Mouse Models of CancerKristoffer Peterson, Ulf J Nilsson, Lise Gravelle, et al.
Journal of Medicinal Chemistry|April 29, 2026
An Orally Available Halothiazole Glycomimetic as a Cancer-Targeting Dual Galectin-1 and Galectin-3 InhibitorFredrik R Zetterberg, Kristoffer Peterson, Ulf J Nilsson, et al.
Journal of Medicinal Chemistry|September 26, 2022
Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic DiseaseFredrik R Zetterberg, Alison MacKinnon, Thomas Brimert, et al.
Frontiers in Pharmacology|August 25, 2022
Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activationDuncan C Humphries, Ross Mills, Cecilia Boz, et al.
Journal of Medicinal Chemistry|May 28, 2024
Discovery of the Selective and Orally Available Galectin-1 Inhibitor GB1908 as a Potential Treatment for Lung CancerFredrik R Zetterberg, Kristoffer Peterson, Ulf J Nilsson, et al.
Pageof 7